Columns

Real-world evidence needed for new work in SMA, other disorders

TREAT-NMD and Aetion have formed a partnership to deliver real-world evidence and promote the development of new treatments for people with rare neuromuscular diseases, including spinal muscular atrophy (SMA). The projects will combine the expertise of the TREAT-NMD global registry network, which collects de-identified data from…

Ambulatory SMA patients on Spinraza show walking gains

More than 1 in 4 ambulatory spinal muscular atrophy (SMA) patients experienced clinically meaningful improvements in walking ability after being treated with Spinraza (nusinersen), according to an analysis of real-world findings in Europe. “Our data demonstrate a positive effect of [Spinraza] treatment on motor function in ambulant pediatric…

Why I bit the bullet and decided to try naturopathy

You know what they say. If something isn’t working, try something else. It’s perfectly logical when you think about it. Why sink time and energy into something that isn’t getting you results? But I’ve found that it’s hard to disinvest from something that, for all intents and purposes, should…

Rare disease awareness offers a brighter future

It’s hard to say exactly what impact rare disease awareness has had on our world. What has it taught us? Those of us with SMA and other rare diseases are keenly aware of the benefits that years of advocacy, research, fundraising, and education have brought to our disability…

Biohaven’s taldefgrobep alfa on FDA’s fast track

The U.S. Food and Drug Administration (FDA) has given fast track designation to Biohaven Pharmaceuticals‘ experimental medicine taldefgrobep alfa for the treatment of spinal muscular atrophy (SMA). The designation is granted to therapies that show potential in addressing serious conditions for which available treatments fall short. It…